Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T22:18:19.952Z.
Consensus retrieved: 2026-10-06T15:17:05.373Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T22:18:19.952Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1f0f34e1a3c3db59aa089d09e3018975893bb9567e33ddb8ff6924431e0b2b95
Forward PE Ratio (N/A) = Dated Quote Price ($49.75) / Consensus Forward EPS ($-1.18)
FORWARD PE RATIO
N/A
Pulse Biosciences, Inc.
Market Cap
$3.44B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Pulse Biosciences, Inc. (PLSE) | $3.44B | N/A |
| Celcuity Inc. (CELC)vs › | $3.47B | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.48B | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 32.05 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.36B | N/A |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.52B | N/A |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.54B | N/A |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 23.33 |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.57B | N/A |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $49.75, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.18 | $-2.36 – $-0.24 | 3 | n/m |
| 2027-12-31 | $-1.25 | $-2.51 – $-0.26 | 3 | n/m |
| 2028-12-31 | $-1.07 | $-1.19 – $-0.89 | 3 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
